Lanthanum

The dosage of Lanthanum is highly individualized based on the patient's dietary phosphate intake and current serum phosphate levels. The goal is to reduce serum phosphate to 5.5 mg/dL or less.

• Starting Dose: The typical starting dose for adults is 1,500 mg per day, divided and taken with meals.
• Titration: Your healthcare provider will monitor your blood phosphate levels every 2 to 3 weeks. Based on these results, the dose may be increased in increments of 750 mg per day.
• Maintenance Dose: Most patients require a total daily dose between 1,500 mg and 3,000 mg. The maximum recommended dose is generally 4,500 mg per day. Higher doses have not been shown to provide additional benefit and may increase the risk of gastrointestinal side effects.

Lanthanum is currently NOT approved for use in pediatric patients. The safety and effectiveness of Lanthanum in children and adolescents under the age of 18 have not been established. There are concerns regarding the potential for Lanthanum to accumulate in developing bones, which could theoretically interfere with growth. Clinical trials in pediatric populations are limited.

Renal Impairment

No dosage adjustment is necessary for patients with renal impairment, as Lanthanum is the treatment for the complications of this condition. Since it is not renally excreted, the level of kidney function does not affect its clearance.

Hepatic Impairment

Because Lanthanum is primarily cleared via the bile, patients with severe hepatic impairment (liver failure) should be monitored closely. However, due to the extremely low systemic absorption, standard dose adjustments are not typically required unless biliary obstruction is present.

Elderly Patients

No specific dose adjustments are required for the elderly. However, since older patients are more likely to have reduced gastrointestinal motility or dental issues, the choice between chewable tablets and oral powder should be made carefully.

To ensure Lanthanum works effectively and to minimize the risk of serious side effects, follow these instructions precisely:

1. 1Take with Meals: Lanthanum must be taken during or immediately after a meal. This allows the drug to mix with food in the stomach and bind to the phosphate before it can be absorbed.
2. 2Chew Thoroughly: If you are using the chewable tablets, you MUST chew them completely before swallowing. Do NOT swallow the tablets whole. Swallowing whole tablets can lead to serious gastrointestinal complications, including bowel obstruction or perforation. If you have difficulty chewing, ask your doctor about the oral powder formulation.
3. 3Oral Powder Usage: Sprinkle the powder onto a small amount of soft food (e.g., applesauce, pudding) and consume it immediately. Do not mix it with liquids, as it will not dissolve.
4. 4Storage: Store Lanthanum at room temperature (68°F to 77°F). Keep the container tightly closed to protect it from moisture.

If you miss a dose of Lanthanum, skip the missed dose and take your next dose at the usual time with your next meal. Do NOT take two doses at once to make up for a missed one. Since Lanthanum works by binding to the phosphate in a specific meal, taking a dose without food is not effective.

An overdose of Lanthanum is unlikely to cause life-threatening systemic toxicity due to its low absorption. However, a large acute ingestion may cause severe gastrointestinal distress, including nausea, vomiting, or abdominal pain. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to dangerous spikes in phosphate levels.

Most side effects associated with Lanthanum are gastrointestinal in nature, as the drug remains primarily within the digestive tract. Common side effects include:

• Nausea and Vomiting: This is the most frequently reported side effect. It often occurs during the first few weeks of treatment as the body adjusts to the medication. Taking the dose with a full meal can help mitigate this.
• Abdominal Pain: Patients may experience cramping or a feeling of fullness in the stomach area.
• Diarrhea or Constipation: Lanthanum can alter bowel habits. Constipation is particularly important to monitor in dialysis patients, who may already have reduced motility.

• Headache: Some patients report mild to moderate headaches shortly after starting therapy.
• Hypocalcemia: Because Lanthanum lowers phosphate, it can sometimes cause a shift in calcium levels. Symptoms include muscle cramps or tingling in the fingers and toes.
• Flatulence (Gas): Increased bloating and gas are common as the medication interacts with food in the gut.

• Lanthanum Deposition: In rare cases of very long-term use, trace amounts of Lanthanum may deposit in the mucosa of the stomach or colon. This is usually discovered during endoscopy and its long-term health impact is currently considered low, but it remains a point of clinical monitoring.
• Allergic Reactions: Skin rashes, itching, or hives have been reported in a small number of patients.

> Warning: Stop taking Lanthanum and call your doctor immediately if you experience any of these symptoms, as they may indicate a life-threatening gastrointestinal event.

• Severe Constipation: If you have not had a bowel movement for several days, this could indicate a blockage.
• Severe Abdominal Pain and Bloating: This may be a sign of bowel obstruction or ileus (where the intestines stop moving).
• Vomiting Blood or Black, Tarry Stools: These are signs of potential gastrointestinal perforation or bleeding.
• Difficulty Swallowing: If the tablets are not chewed properly, they can become lodged in the esophagus.

Because Lanthanum is a heavy metal, there has been historical concern regarding its accumulation in the body over decades.

• Bone Accumulation: Studies have shown that Lanthanum can deposit in the bone matrix. Current data from clinical trials lasting up to 5 years suggests that this does not adversely affect bone strength or mineralization in adults, but long-term data (10-20 years) is still being gathered.
• Liver Sequestration: Trace amounts have been found in liver biopsies of long-term users. There is currently no evidence that this causes liver dysfunction, but patients with pre-existing liver disease should be monitored.

There are currently no FDA Black Box Warnings for Lanthanum Carbonate. However, the FDA has issued safety communications emphasizing the risk of Gastrointestinal Obstruction and Perforation, particularly in patients who do not chew the tablets thoroughly or who have pre-existing bowel conditions such as Crohn's disease or a history of abdominal surgery.

Report any unusual symptoms to your healthcare provider. Your doctor may perform periodic X-rays or endoscopies if gastrointestinal complications are suspected, as Lanthanum is radiopaque (it shows up on X-rays).

Lanthanum is a highly effective medication for phosphate control, but it carries specific risks related to the gastrointestinal system. It is imperative that patients understand the physical requirements of taking this drug, specifically the need for thorough chewing of tablets.

No FDA black box warnings for Lanthanum. However, the manufacturer and the FDA emphasize that the risk of serious GI adverse events is the primary safety concern.

• Gastrointestinal Disorders: Lanthanum should be used with extreme caution in patients with a history of bowel obstruction, ileus, or severe constipation. It is also contraindicated in patients with complete bowel obstruction. If you have a history of stomach ulcers, Crohn’s disease, or ulcerative colitis, discuss this with your doctor.
• Abdominal Surgery: Patients who have recently undergone abdominal surgery are at a higher risk for bowel obstruction and should be monitored closely when starting Lanthanum.
• Radiopacity: Lanthanum is a heavy metal and is radiopaque. This means it will show up on abdominal X-rays, potentially mimicking other medical conditions or obscuring the view of the intestines. If you are scheduled for an X-ray, CT scan, or MRI of the abdomen, inform the radiologist that you are taking Lanthanum.
• Dental Health: Because the tablets must be chewed, patients with poor dental health or dentures may find the tablets difficult to consume. In such cases, the oral powder formulation is preferred to prevent dental damage or incomplete chewing.

To ensure safety and efficacy, your healthcare provider will require the following:

• Serum Phosphate: Monitored every 2-3 weeks during dose titration and monthly once stable.
• Serum Calcium: Monitored regularly to ensure the calcium-phosphate product remains in a safe range.
• PTH Levels: Monitored every 3-6 months to assess the impact on bone metabolism.

Lanthanum is not known to cause drowsiness or impair cognitive function. It is generally considered safe to drive or operate machinery while taking this medication.

There is no direct chemical interaction between Lanthanum and alcohol. However, alcohol consumption can complicate the management of Chronic Kidney Disease and may contribute to gastrointestinal irritation. Patients should consult their nephrologist regarding safe levels of alcohol intake.

Stopping Lanthanum suddenly will lead to a rapid increase in serum phosphate levels, which can increase the risk of cardiovascular events and bone damage. If you must stop taking Lanthanum (for example, before a medical procedure), your doctor will provide a specific plan to manage your phosphate levels through diet or alternative binders.

> Important: Discuss all your medical conditions, especially any history of bowel problems, with your healthcare provider before starting Lanthanum.

There are no drugs that are strictly contraindicated for use with Lanthanum based on chemical reactivity alone. However, Lanthanum can bind to other medications in the gut, preventing them from being absorbed. This is known as a chelation interaction.

• Quinolone Antibiotics (e.g., Ciprofloxacin, Levofloxacin): Lanthanum can significantly reduce the absorption of these antibiotics. They should be taken at least 1 hour before or 4 hours after taking Lanthanum.
• Tetracycline Antibiotics (e.g., Doxycycline): Similar to quinolones, Lanthanum binds to tetracyclines. Space these medications at least 2 hours apart from Lanthanum.
• Levothyroxine: This thyroid medication is highly sensitive to binders. Taking it too close to Lanthanum can lead to hypothyroidism. Space doses by at least 4 hours.

• ACE Inhibitors (e.g., Enalapril, Lisinopril): Some studies suggest a slight reduction in absorption. It is best to take these medications at least 1 hour before or 3 hours after Lanthanum.
• Statins: While not a major interaction, monitoring cholesterol levels is advised if Lanthanum is started while on a stable statin dose.
• Anti-Seizure Medications: Drugs like Valproate may have altered absorption. Monitor blood levels of the anti-seizure medication closely.

• High-Phosphate Foods: While not a drug-drug interaction, consuming foods extremely high in phosphorus (like soda, processed meats, and dairy) can overwhelm the binding capacity of Lanthanum, making the drug appear less effective.
• Dairy: High calcium intake alongside Lanthanum is generally safe, but excessive calcium can increase the risk of vascular calcification in ESRD patients.

• Multivitamins with Minerals: Supplements containing iron, magnesium, or zinc should be taken at least 2 hours apart from Lanthanum, as Lanthanum may bind to these minerals and prevent their absorption.
• St. John's Wort: No known metabolic interaction, but always inform your doctor of herbal use.

• Abdominal X-rays: As mentioned, Lanthanum is radiopaque and can interfere with the interpretation of abdominal imaging studies.
• Phosphate Assays: Lanthanum does not typically interfere with the chemical laboratory testing of blood phosphate, but it significantly reduces the actual levels in the blood.

For each major interaction, the mechanism is typically physical binding (chelation) in the gut lumen. This reduces the bioavailability of the co-administered drug, leading to reduced efficacy. The management strategy is always temporal spacing—separating the administration times of the two drugs.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially other binders or antibiotics.

Lanthanum must NEVER be used in the following circumstances:

• Bowel Obstruction: If a patient has a known or suspected blockage in the small or large intestine, Lanthanum can worsen the condition and lead to a life-threatening bowel perforation. The mechanism is the physical accumulation of the non-absorbed drug at the site of the blockage.
• Hypophosphatemia: Patients with already low phosphate levels should not take Lanthanum, as it will drive levels dangerously low, potentially causing muscle weakness, respiratory failure, or coma.
• Hypersensitivity: Any patient with a known allergy to Lanthanum Carbonate or any of the inactive ingredients in the tablets/powder should avoid this medication.

Conditions requiring careful risk-benefit analysis include:

• Severe Constipation: Patients with chronic, severe constipation are at higher risk for developing an obstruction while on Lanthanum.
• Active Peptic Ulcer Disease: The presence of ulcers may increase the risk of gastrointestinal bleeding or perforation when taking large amounts of chewable tablets.
• Inflammatory Bowel Disease (IBD): Conditions like Crohn's disease can cause narrowing (strictures) of the intestines, which increases the risk of the medication getting stuck.
• Severe Hepatic Impairment: While absorption is low, the primary route of systemic clearance is the bile. In patients with biliary obstruction, systemic levels could theoretically rise.

There is no known cross-sensitivity between Lanthanum and other phosphate binders like Sevelamer or Calcium Acetate, as they are chemically unrelated. However, patients who have had allergic reactions to other heavy metal-based compounds should be monitored closely.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of abdominal surgeries or digestive disorders, before prescribing Lanthanum.

Lanthanum is categorized as Pregnancy Category C (under the older FDA system). There are no adequate and well-controlled studies of Lanthanum in pregnant women. Animal studies have shown that Lanthanum can cross the placental barrier and accumulate in fetal bone. Because phosphate control is essential during pregnancy for the health of both the mother and the fetus, healthcare providers must weigh the risks of Lanthanum against the risks of uncontrolled hyperphosphatemia. Alternative binders like calcium acetate are often preferred during pregnancy.

It is unknown whether Lanthanum is excreted in human milk. However, because systemic absorption in the mother is extremely low, the amount of Lanthanum likely to reach the infant via breast milk is negligible. Nevertheless, caution should be exercised. The potential for Lanthanum to interfere with the infant's mineral absorption should be considered. Consult your doctor before breastfeeding while on this medication.

Lanthanum is NOT approved for pediatric use. The primary concern is the potential for Lanthanum to deposit in developing bone tissue. In animal studies, high doses of Lanthanum interfered with bone mineralization in young, growing animals. Until more data is available, other phosphate binders are typically used for children with CKD.

Clinical studies have included a significant number of patients aged 65 and over, and no overall differences in safety or effectiveness have been observed compared to younger adults. However, elderly patients are more prone to gastrointestinal motility issues and may have weaker dentition, making the oral powder a better choice than chewable tablets for many in this age group.

Lanthanum is specifically designed for patients with severe renal impairment (ESRD). No dose adjustment is needed based on the degree of kidney failure, as the drug's action is local to the gut and it is not cleared by the kidneys.

No formal studies have been conducted in patients with hepatic impairment. While systemic absorption is low, Lanthanum is cleared via the bile. Patients with severe liver disease or biliary obstruction should be monitored for signs of systemic accumulation, though the clinical risk is considered low.

> Important: Special populations require individualized medical assessment. Always inform your nephrologist if you are planning to become pregnant or have liver concerns.

Lanthanum Carbonate is a non-calcium, non-aluminum phosphate binder. Its molecular mechanism involves the release of trivalent Lanthanum ions (La3+) in the acidic environment of the stomach. These ions have a high affinity for dietary phosphate (PO43-). The resulting chemical reaction creates Lanthanum Phosphate (LaPO4), an extremely stable and insoluble salt. This salt remains in the gastrointestinal lumen and is excreted in the feces. By binding phosphate in the gut, Lanthanum prevents its absorption into the systemic circulation, thereby lowering serum phosphorus levels.

The pharmacodynamic effect of Lanthanum is directly proportional to the amount of dietary phosphate present. It does not have a systemic 'onset of action' in the traditional sense; rather, it begins binding phosphate as soon as it mixes with food in the stomach. The duration of effect is limited to the time the drug remains in the GI tract. Tolerance to the phosphate-binding effect does not develop over time.

| Parameter | Value |

|---|---|

| Bioavailability | < 0.00127% |

| Protein Binding | > 99% (to Albumin) |

| Half-life (Plasma) | 53 hours (trace systemic fraction) |

| Tmax | Not applicable (local action) |

| Metabolism | None (Elemental) |

| Excretion | Fecal (>99%), Biliary (trace) |

• Molecular Formula: La2(CO3)3 · xH2O
• Molecular Weight: 457.8 g/mol (anhydrous)
• Solubility: Insoluble in water; soluble in mineral acids (like stomach acid) where it dissociates into ions.
• Description: Lanthanum is a rare earth element (lanthanide series). The carbonate salt is a white to off-white powder used in pharmaceutical formulations.

Lanthanum is classified as a Phosphate Binder and a Non-Calcium, Non-Aluminum Mineral Antagonist. Related medications include Sevelamer (a polymer-based binder), Calcium Acetate, and Sucroferric Oxyhydroxide (an iron-based binder).